Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.

Translational research : the journal of laboratory and clinical medicine - 1 Sept 2026

Corrêa Lucas Maciel de Almeida, Brandão Luiggi Kevin Virgino, Delmiro Silva Yan Roberth, Ferreira Guilherme Diniz, Mazur Gabriel Rian, Arruda Sicília Lins Peixoto

Abstract excerpt

Autosomal dominant polycystic kidney disease (ADPKD) remains therapeutically anchored to vasopressin V2-receptor antagonism, yet progression heterogeneity and persistent unmet need increasingly suggest residual disease biology beyond cAMP-centered control. Converging experimental and observational human phenotype data suggest that metabolic reprogramming, mitochondrial dysfunction, impaired fatty-acid oxidation,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glucagon-Like Peptide-1 Receptor
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycystic Kidney, Autosomal Dominant

Share to Translational Research, Biomedical

Source

Identifiers

PMID: 42398811
DOI: 10.1016/j.trsl.2026.07.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.PMID 42398811Read ↗

Phenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic DisordersSemantic proximity Read ↗

Phenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic DisordersSemantic proximity Read ↗

Insights Into the Molecular Mechanisms of Polycystic Kidney DiseasesSemantic proximity Read ↗

Multi-Omics Integration Reveals Lipid Metabolic Reprogramming as a Driver of Cystogenesis in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Semantic proximity Read ↗

Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.Semantic proximity Read ↗

ALG8-Driven Metabolic Reprogramming in Polycystic Kidney Disease: A Systematic Synthesis of Evidence Linking Glycosylation Defects to Metabolic Signaling.Semantic proximity Read ↗

Autosomic dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease.Semantic proximity Read ↗

Endoplasmic reticulum-mitochondrion disconnection promotes metabolic reprogramming and cystogenesis in polycystic kidney diseaseSemantic proximity Read ↗

New treatment paradigms for ADPKD: moving towards precision medicine.Semantic proximity Read ↗

Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.Semantic proximity Read ↗

Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.Semantic proximity Read ↗

Autosomal Dominant Polycystic Kidney DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.